ITCC-047 REGORAFENIB
A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard therapy
Promotor Name : BAYER
Investigator Name : B. GEOERGER
Trial registered on clinicaltrial.gov: NCT02085148
